A Retrospective Review of the Management of Patients Following a Malignancy Diagnosis on Biologic Therapies for the Treatment of Dermatological Disorders

Overview

Journal JAAD Case Rep

Specialty Dermatology

Date 2023 Sep 4

PMID 37664445

Authors

Paula Finnegan

Kashif Ahmad

Muriel Sadlier

Maeve Lynch

Affiliations

Soon will be listed here.

Citing Articles

Regression of multiple intracranial meningiomas after cessation of long-term synthetic progesterone (megestrol) medication: case report and autopsy.

AlDoheyan T, Del Bigio M Free Neuropathol. 2024; 5:27.

PMID: 39473896 PMC: 11519963. DOI: 10.17879/freeneuropathology-2024-5813.

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma.

Koroneos G, Nicolopoulos J, Dolianitis C JAAD Case Rep. 2024; 48:108-111.

PMID: 38813065 PMC: 11134539. DOI: 10.1016/j.jdcr.2024.03.023.

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.

Battista T, Gallo L, Martora F, Fattore D, Potestio L, Cacciapuoti S J Clin Med. 2024; 13(7).

PMID: 38610706 PMC: 11012886. DOI: 10.3390/jcm13071940.

References

Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni R . Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat. 2021; 33(3):1638-1642. DOI: 10.1080/09546634.2021.1886231. View

Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M . Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?. J Dermatolog Treat. 2021; 33(5):2495-2502. DOI: 10.1080/09546634.2021.1970706. View

Papp K, Melosky B, Sehdev S, Hotte S, Beecker J, Kirchhof M . Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb). 2023; 13(4):867-889. PMC: 10060504. DOI: 10.1007/s13555-023-00905-3. View

Wang D, Fernandez A, Calabrese C, Calabrese L . Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin Exp Dermatol. 2018; 44(1):113-115. DOI: 10.1111/ced.13630. View

Balato A, Lembo S, Cirillo T, Megna M, Raimondo A, DI Costanzo L . Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia. Case Rep Dermatol. 2011; 3(1):60-3. PMC: 3073755. DOI: 10.1159/000324344. View

Menter A, Gelfand J, Connor C, Armstrong A, Cordoro K, Davis D . Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020; 82(6):1445-1486. DOI: 10.1016/j.jaad.2020.02.044. View

Jin J, Ahlstrom J, Sweeney N, Liao W . Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing. Dermatol Ther (Heidelb). 2020; 10(4):815-827. PMC: 7367969. DOI: 10.1007/s13555-020-00416-5. View

Papp K, Reich K, Leonardi C, Kircik L, Chimenti S, Langley R . Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis.... J Am Acad Dermatol. 2015; 73(1):37-49. DOI: 10.1016/j.jaad.2015.03.049. View

Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csorgo Z, Boonen H . EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021; 35(2):281-317. DOI: 10.1111/jdv.16926. View

10.

Lebwohl M, Deodhar A, Griffiths C, Menter M, Poddubnyy D, Bao W . The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021; 185(5):935-944. DOI: 10.1111/bjd.20136. View

11.

Gkalpakiotis S, Arenberger P, Fridman M, Arenbergerova M . Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. Dermatol Ther. 2017; 30(6). DOI: 10.1111/dth.12522. View

12.

Lasagni C, Bigi L, Conti A, Pellacani G . Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J Dermatolog Treat. 2018; 29(sup2):5-8. DOI: 10.1080/09546634.2018.1543843. View

13.

Gambardella A . Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. Case Rep Dermatol. 2019; 11(Suppl 1):11-16. PMC: 6816125. DOI: 10.1159/000501993. View

14.

Bellinato F, Gisondi P, Maurelli M, Girolomoni G . IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatol Ther. 2021; 34(2):e14889. DOI: 10.1111/dth.14889. View

15.

Fiorentino D, Ho V, Lebwohl M, Leite L, Hopkins L, Galindo C . Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017; 77(5):845-854.e5. DOI: 10.1016/j.jaad.2017.07.013. View

16.

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

17.

Di Lernia V, Casanova D, Ricci C . Apremilast in patients with history of malignancy: a real-life, single-center experience. Int J Dermatol. 2020; 60(1):e22-e24. DOI: 10.1111/ijd.15093. View

18.

Patel S, Patel T, Kerdel F . The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol. 2015; 55(5):487-93. DOI: 10.1111/ijd.13129. View

19.

Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P . Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Dermatol Ther (Heidelb). 2022; 12(11):2613-2626. PMC: 9588094. DOI: 10.1007/s13555-022-00797-9. View

20.

Ghazanfar M, Karlsmark T, Danielsen P, Thomsen S . Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. Clin Case Rep. 2019; 7(7):1350-1351. PMC: 6637360. DOI: 10.1002/ccr3.2225. View